vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and VICOR CORP (VICR). Click either name above to swap in a different company.
VICOR CORP is the larger business by last-quarter revenue ($113.0M vs $62.1M, roughly 1.8× Cytek Biosciences, Inc.). VICOR CORP runs the higher net margin — 18.3% vs -70.9%, a 89.2% gap on every dollar of revenue. On growth, VICOR CORP posted the faster year-over-year revenue change (20.2% vs 8.1%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 14.7%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
CTKB vs VICR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $113.0M |
| Net Profit | $-44.1M | $20.7M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | 59.7% |
| Net Margin | -70.9% | 18.3% |
| Revenue YoY | 8.1% | 20.2% |
| Net Profit YoY | -557.1% | 713.9% |
| EPS (diluted) | — | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.0M | ||
| Q4 25 | $62.1M | $107.3M | ||
| Q3 25 | $52.3M | $110.4M | ||
| Q2 25 | $45.6M | $96.0M | ||
| Q1 25 | $41.5M | $94.0M | ||
| Q4 24 | $57.5M | $96.2M | ||
| Q3 24 | $51.5M | $93.2M | ||
| Q2 24 | $46.6M | $85.9M |
| Q1 26 | — | $20.7M | ||
| Q4 25 | $-44.1M | $46.5M | ||
| Q3 25 | $-5.5M | $28.3M | ||
| Q2 25 | $-5.6M | $41.2M | ||
| Q1 25 | $-11.4M | $2.5M | ||
| Q4 24 | $9.6M | $10.2M | ||
| Q3 24 | $941.0K | $11.6M | ||
| Q2 24 | $-10.4M | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | 52.9% | 55.4% | ||
| Q3 25 | 52.7% | 57.5% | ||
| Q2 25 | 52.3% | 95.9% | ||
| Q1 25 | 48.6% | 47.2% | ||
| Q4 24 | 58.5% | 52.4% | ||
| Q3 24 | 56.3% | 49.1% | ||
| Q2 24 | 54.6% | 49.8% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | -9.0% | 14.6% | ||
| Q3 25 | -17.6% | 18.9% | ||
| Q2 25 | -23.3% | 47.3% | ||
| Q1 25 | -36.1% | -0.2% | ||
| Q4 24 | 5.2% | 9.6% | ||
| Q3 24 | -8.2% | 5.8% | ||
| Q2 24 | -18.3% | 0.2% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | -70.9% | 43.4% | ||
| Q3 25 | -10.5% | 25.6% | ||
| Q2 25 | -12.2% | 42.9% | ||
| Q1 25 | -27.5% | 2.7% | ||
| Q4 24 | 16.8% | 10.7% | ||
| Q3 24 | 1.8% | 12.4% | ||
| Q2 24 | -22.4% | -1.4% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | — | $1.01 | ||
| Q3 25 | — | $0.63 | ||
| Q2 25 | — | $0.91 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.24 | ||
| Q3 24 | — | $0.26 | ||
| Q2 24 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $404.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $754.1M |
| Total Assets | $461.5M | $804.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $404.2M | ||
| Q4 25 | $90.9M | $402.8M | ||
| Q3 25 | $93.3M | $362.4M | ||
| Q2 25 | $75.5M | $338.5M | ||
| Q1 25 | $95.3M | $296.1M | ||
| Q4 24 | $98.7M | $277.3M | ||
| Q3 24 | $162.3M | $267.6M | ||
| Q2 24 | $177.9M | $251.9M |
| Q1 26 | — | $754.1M | ||
| Q4 25 | $341.7M | $711.6M | ||
| Q3 25 | $378.6M | $630.1M | ||
| Q2 25 | $377.6M | $608.6M | ||
| Q1 25 | $379.6M | $580.3M | ||
| Q4 24 | $395.7M | $570.1M | ||
| Q3 24 | $385.5M | $554.6M | ||
| Q2 24 | $389.1M | $537.2M |
| Q1 26 | — | $804.9M | ||
| Q4 25 | $461.5M | $785.8M | ||
| Q3 25 | $494.9M | $710.2M | ||
| Q2 25 | $493.3M | $693.5M | ||
| Q1 25 | $482.6M | $665.0M | ||
| Q4 24 | $499.5M | $641.1M | ||
| Q3 24 | $491.2M | $632.8M | ||
| Q2 24 | $483.7M | $613.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | — |
| Free Cash FlowOCF − Capex | $-1.8M | — |
| FCF MarginFCF / Revenue | -2.9% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-771.0K | $15.7M | ||
| Q3 25 | $-3.9M | $38.5M | ||
| Q2 25 | $108.0K | $65.2M | ||
| Q1 25 | $-125.0K | $20.1M | ||
| Q4 24 | $2.0M | $10.1M | ||
| Q3 24 | $13.2M | $22.6M | ||
| Q2 24 | $6.2M | $15.6M |
| Q1 26 | — | — | ||
| Q4 25 | $-1.8M | $10.2M | ||
| Q3 25 | $-4.6M | $34.5M | ||
| Q2 25 | $-1.5M | $59.0M | ||
| Q1 25 | $-974.0K | $15.6M | ||
| Q4 24 | $1.1M | $8.4M | ||
| Q3 24 | $12.2M | $14.1M | ||
| Q2 24 | $5.2M | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | -2.9% | 9.5% | ||
| Q3 25 | -8.7% | 31.2% | ||
| Q2 25 | -3.2% | 61.5% | ||
| Q1 25 | -2.3% | 16.6% | ||
| Q4 24 | 1.9% | 8.7% | ||
| Q3 24 | 23.7% | 15.2% | ||
| Q2 24 | 11.0% | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 5.2% | ||
| Q3 25 | 1.3% | 3.6% | ||
| Q2 25 | 3.5% | 6.5% | ||
| Q1 25 | 2.0% | 4.8% | ||
| Q4 24 | 1.6% | 1.8% | ||
| Q3 24 | 2.0% | 9.1% | ||
| Q2 24 | 2.3% | 7.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.58× | ||
| Q1 25 | — | 7.93× | ||
| Q4 24 | 0.21× | 0.99× | ||
| Q3 24 | 14.05× | 1.95× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
